Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care (DMAR)

Launched by QHSLAB, INC. · Sep 16, 2024

Keywords

ClinConnect Summary

The clinical trial, titled "Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care" (DMAR), is exploring how digital tools can help people manage allergic rhinitis, a condition that causes sneezing, runny nose, and other allergy symptoms. The study will compare two groups of adults: one group will receive standard care for their allergies, while the other group will use standard care along with digital tools that help track symptoms, remind them to take their medication, and provide personalized feedback. This trial aims to see if these digital tools can lead to better control of allergy symptoms, improved treatment adherence, and a better quality of life over a 12-month period.

To participate in this study, adults aged 18 to 65 who have been diagnosed with allergic rhinitis or sinusitis for at least six months and have ongoing symptoms may be eligible. Participants will be asked to share their experiences with the digital tools and how they manage their symptoms throughout the study. It's important to note that individuals with certain health conditions or those who are pregnant or breastfeeding cannot participate. This trial is not yet recruiting, but if you're interested, keep an eye out for updates on how to get involved!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 18-65 years.
• • Clinically diagnosed with allergic rhinitis and/or sinusitis for at least 6 months.
• • SNOT-22 score of ≥20, indicating uncontrolled allergic rhinitis.
• • If Currently receiving treatment for allergic rhinitis and willing to continue treatment during the study.
• • Able and willing to provide informed consent electronically and comply with the study procedures.
• Exclusion Criteria:
• • Individuals under 18 or over 65 years of age.
• • Pregnant or breastfeeding women.
• • Recent surgical treatment for nasal polyps (within the last 3 months).
• • Patients with cystic fibrosis, purulent nasal infections, or any other disease likely to interfere with the study parameters.
• • Individuals with severe or unstable concurrent diseases or psychological disorders that may compromise participation in the study.